DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...
How big is the sensor patch market, and why is it growing so fast? The global sensor patch market is valued at USD 7.9 ...
A Type 2 diabetes patient prepares to attach his Dexcom sensor, part of a continuous glucose monitoring system, on his ...
A new methodological perspective uses the Sinocare iCan i3 real-world accuracy study to argue that continuous glucose ...
Verywell Health on MSN
Why CGMs are becoming a wellness trend for your patients
It seems like everyone’s tracking their blood sugar now. Should they be?
Domestic pharmaceutical companies continue to enter the continuous glucose monitoring, CGM, business. As Daewoong ...
DexCom (DXCM) stock jumps as peer-reviewed data from a study for the G7 insulin pump in type 2 diabetes boost its Medicare coverage hopes.
DexCom, Inc. announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the ...
The results come as Dexcom is awaiting a decision from the Centers for Medicare and Medicaid Services to expand Medicare ...
(NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine ...
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results